The Use of Ruxolitinib in MPN

Experts discuss key data and NCCN guidelines for ruxolitinib, the FDA approval for patients with intermediate to high-risk disease, and personal use in practice.


For more resources and information regarding anticancer targeted therapies:

targeted oncology,oncology,cancer,